Emerging treatments for post-transplantation diabetes mellitus

Nature Reviews Nephrology

Volumn 11, Issue 8, 2015, Pages 465-477

  Jenssen, Trond ^a   Hartmann, Anders ^b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; AMYLIN DERIVATIVE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; BILE ACID SEQUESTRANT; CALCINEURIN INHIBITOR; CANAGLIFLOZIN; CYCLOSPORIN A; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INSULIN; LINAGLIPTIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; RAPAMYCIN; REPAGLINIDE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; TACROLIMUS; UNINDEXED DRUG; VILDAGLIPTIN; GLUCOSE;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DIET THERAPY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; KINESIOTHERAPY; LIFESTYLE MODIFICATION; NONHUMAN; PHYSICAL ACTIVITY; POSTTRANSPLANTATION DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; UREMIA; ALGORITHM; ANTAGONISTS AND INHIBITORS; POSTOPERATIVE COMPLICATIONS;

ALGORITHMS; DIABETES MELLITUS; GLUCOSE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 84938196381     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2015.59     Document Type: Review

References (143)

1. Davidson J., et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 75, SS3-SS24 (2003
2. Wilkinson A., et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin. Transplant. 19, 291-298 (2005
3. Sharif A., et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am. J. Transplant. 14, 1992-2000 (2014
4. Cosio F. G., et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 67, 2415-2421 (2005
5. Kasiske B. L., Snyder J. J., Gilbertson D. & Matas A. J. Diabetes mellitus after kidney transplantation in the United States. Am. J. Transplant. 3, 178-185 (2003
6. Valderhaug T. G., et al. The association of early post-transplant glucose levels with long-term mortality. Diabetologia 54, 1341-1349 (2011
7. Hecking M., et al. Glucose metabolism after renal transplantation. Diabetes Care 36, 2763-2771 (2013
8. Hjelmesaeth J., et al. The impact of impaired insulin release and insulin resistance on glucose intolerance after renal transplantation. Clin. Transplant. 16, 389-396 (2002
9. Vincenti F., et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am. J. Transplant. 7, 1506-1514 (2007
10. Chakkera H. A., Weil E. J., Pham P. T., Pomeroy J. & Knowler W. C. Can new-onset diabetes after kidney transplant be prevented?. Diabetes Care 36, 1406-1412 (2013
11. Hjelmesaeth J., Midtvedt K., Jenssen T. & Hartmann A. Insulin resistance after renal transplantation: impact of immunosuppressive and antihypertensive therapy. Diabetes Care 24, 2121-2126 (2001
12. Hornum M., et al. New-onset diabetes mellitus after kidney transplantation in Denmark. Clin. J. Am. Soc. Nephrol. 5, 709-716 (2010
13. Voytovich M. H., et al. Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol. Dial. Transplant. 20, 413-418 (2005
14. Werzowa J., et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation 95, 456-462 (2013
15. Delaunay F., et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J. Clin. Invest. 100, 2094-2098 (1997
16. Andrews R. C. & Walker B. R. Glucocorticoids and insulin resistance: old hormones, new targets. Clin. Sci. (Lond.) 96, 513-523 (1999
17. Hjelmesaeth J., et al. The impact of short-term ciclosporin A treatment on insulin secretion and insulin sensitivity in man. Nephrol. Dial. Transplant. 22, 1743-1749 (2007
18. Jenssen T. & Hartmann A. Prevention and management of transplant-associated diabetes. Expert. Opin. Pharmacother. 12, 2641-2655 (2011
19. Alberti K. G. & Zimmet P. Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine 15, 539-553 (1998
20. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 34, S62-S69 (2011
21. Eide I. A., et al. Limitations of hemoglobin A1c for the diagnosis of posttransplant diabetes mellitus. Transplantation 99, 629-635 (2014
22. Inzucchi S. E., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35, 1364-1379 (2012
23. Cole E. H., Johnston O., Rose C. L. & Gill J. S. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin. J. Am. Soc. Nephrol. 3, 814-821 (2008
24. Hjelmesaeth J., et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int. 69, 588-595 (2006
25. Wolfe R. A., et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med. 341, 1725-1730 (1999
26. Miller L. W. Cardiovascular toxicities of immunosuppressive agents. Am. J. Transplant. 2, 807-818 (2002
27. [No authors listed] Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe. Lancet 354, 617-621 (1999
28. Valderhaug T. G., et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 88, 429-434 (2009
29. Valderhaug T. G., et al. Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses. Transplantation 94, 714-720 (2012
30. Dinneen S., Gerich J. & Rizza R. Carbohydrate metabolism in non insulin dependent diabetes mellitus. N. Engl. J. Med. 327, 707-713 (1992
31. Grodsky G. M. A new phase of insulin secretion. How will it contribute to our understanding of beta-cell function?. Diabetes 38, 673-678 (1989
32. Pimenta W., et al. Pancreatic β-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 273, 1855-1861 (1995
33. Weyer C., Bogardus C., Mott D. M. & Pratley R. E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest. 104, 787-794 (1999
34. van Haeften T. W., et al. Relative contributions of beta-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia. Metabolism 49, 1318-1325 (2000
35. Drucker D. J. & Nauck M. A. The incretin system: glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors in type 2 diabetes. Lancet 368, 1696-1705 (2006
36. Strom Halden T. A., Asberg A., Vik K., Hartmann A. & Jenssen T. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol. Dial. Transplant. 29, 926-933 (2014
37. Ferrannini E., et al. beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J. Clin. Endocrinol. Metab. 90, 493-500 (2005
38. Gerich J. E., et al. Contribution of impaired muscle glucose clearance to reduced postabsorptive systemic glucose clearance in NIDDM. Diabetes 39, 211-216 (1990
39. Kahn S. E., et al. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42, 1663-1672 (1993
40. Gerich J. E. Physiology of glucose homeostasis. Diabetes Obes. Metab. 2, 345-350 (2000
41. Muller W. A., Faloona G. R., Aguilar-Parada E. & Unger R. H. Abnormal α-cell function in diabetes. Response to carbohydrate and protein ingestion. N. Engl. J. Med. 283, 109-115 (1970
42. Consoli A., Nurjhan N., Capani F. & Gerich J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38, 550-557 (1989
43. Yki-Jarvinen H. Acute and chronic effects of hyperglycaemia on glucose metabolism: implications for the development of new therapies. Diabet. Med. 14 (Suppl. 3), S32-S37 (1997
44. Segaert M. F., De S. C., Vandewiele I. & Verbanck J. Drug interaction induced rhabdomyolysis. Nephrol. Dial. Transplant. 11, 1846-1847 (1996
45. Maggio T. G. & Bartels D. W. Increased cyclosporine blood concentrations due to verapamil administration. Drug Intell. Clin. Pharm. 22, 705-707 (1988
46. Drugs.com [Internet]. Mycophenolate mofetil drug interactions [online], http://www.drugs.com/drug-interactions/mycophenolate-mofetil.html (2015
47. Arora S., Tangirala B., Osadchuk L. & Sureshkumar K. K. Belatacept: a new biological agent for maintenance immunosuppression in kidney transplantation. Expert Opin. Biol. Ther. 12, 965-979 (2012
48. Su V. C., Harrison J., Rogers C. & Ensom M. H. Belatacept: a new biologic and its role in kidney transplantation. Ann. Pharmacother. 46, 57-67 (2012
49. Gerich J. E. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet. Med. 27, 136-142 (2010
50. Meyer C., Dostou J. M. & Gerich J. E. Role of the human kidney in glucose counterregulation. Diabetes 48, 943-948 (1999
51. Bruderer S. G., et al. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK-a nested case-control analysis. Diabetes Obes. Metab. (2014
52. Koch M., Gradaus F., Schoebel F. C., Leschke M. & Grabensee B. Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol. Dial. Transplant. 12, 1187-1191 (1997
53. Frier B. M., Schernthaner G. & Heller S. R. Hypoglycemia and cardiovascular risks. Diabetes Care 34 (Suppl. 2), S132-S137 (2011
54. Robinson R. T., et al. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycaemia. Diabetes 52, 1469-1474 (2003
55. Koivikko M. L., et al. Effects of controlled hypoglycaemia on cardiac repolarisation in patients with type 1 diabetes. Diabetologia 51, 426-435 (2008
56. Dichtwald S., Weinbroum A. A., Sorkine P., Ekstein M. P. & Dahan E. Metformin-associated lactic acidosis following acute kidney injury. Efficacious treatment with continuous renal replacement therapy. Diabet. Med. 29, 245-250 (2012
57. Wang C. H., Weisel R. D., Liu P. P., Fedak P. W. & Verma S. Glitazones and heart failure: critical appraisal for the clinician. Circulation 107, 1350-1354 (2003
58. Sharif A., Moore R. & Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 85, 353-358 (2008
59. Zelle D. M., et al. Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients. Clin. J. Am. Soc. Nephrol. 6, 898-905 (2011
60. Kim Y., et al. Patients with persistent new-onset diabetes after transplantation have greater weight gain after kidney transplantation. J. Korean Med. Sci. 28, 1431-1434 (2013
61. Tokodai K., et al. Posttransplant increase of body mass index is associated with new-onset diabetes mellitus after kidney transplantation. Tohoku J. Exp. Med. 229, 227-232 (2013
62. Jardine A. G., Gaston R. S., Fellstrom B. C. & Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 378, 1419-1427 (2011
63. Schacke H., Docke W. D. & Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96, 23-43 (2002
64. Woodle E. S., et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann. Surg. 248, 564-577 (2008
65. Rostaing L., et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 79, 807-814 (2005
66. Midtvedt K., et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J. Am. Soc. Nephrol. 15, 3233-3239 (2004
67. Yates C. J., Fourlanos S., Colman P. G. & Cohney S. J. Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation. Nephrol. Dial. Transplant. 29, 698-705 (2014
68. Ekberg H., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 357, 2562-2575 (2007
69. Webster A. C., Woodroffe R. C., Taylor R. S., Chapman J. R. & Craig J. C. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 331, 810 (2005
70. Johnston O., Rose C. L., Webster A. C. & Gill J. S. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J. Am. Soc. Nephrol. 19, 1411-1418 (2008
71. Flechner S. M., et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am. J. Transplant. 11, 1633-1644 (2011
72. Suszynski T. M., et al. Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. Am. J. Transplant. 13, 961-970 (2013
73. Vanrenterghem Y., et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 91, 976-983 (2011
74. Cusi K., Consoli A. & DeFronzo R. A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab 81, 4059-4067 (1996
75. Kahn C. R., Chen L. & Cohen S. E. Unraveling the mechanism of action of thiazolidinediones. J. Clin. Invest 106, 1305-1307 (2000
76. Hasan F. M., Alsahli M. & Gerich J. E. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res. Clin. Pract. 104, 297-322 (2014
77. Inzucchi S. E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287, 360-372 (2002
78. Thule P. M. & Umpierrez G. Sulfonylureas: a new look at old therapy. Curr. Diab. Rep. 14, 473 (2014
79. UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837-853 (1998)
80. Roumie C. L., et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann. Intern. Med. 157, 601-610 (2012
81. Mocanu M. M., et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 103, 3111-3116 (2001
82. Turk T., et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am. J. Transplant. 6, 842-846 (2006
83. Voytovich M. H., et al. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients. Clin. Transplant. 21, 246-251 (2007
84. Califf R. M., et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am. Heart J. 156, 623-632 (2008
85. Holman R. R., et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 362, 1463-1476 (2010
86. McMurray J. J., et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 362, 1477-1490 (2010
87. Kolata G. B. The phenformin ban: is the drug an imminent hazard?. Science 203, 1094-1096 (1979
88. Shaw J. S., Wilmot R. L. & Kilpatrick E. S. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet. Med. 24, 1160-1163 (2007
89. Shivaswamy V., Bennett R. G., Clure C. C., Larsen J. L. & Hamel F. G. Metformin improves immunosuppressant induced hyperglycemia and exocrine apoptosis in rats. Transplantation 95, 280-284 (2013
90. McCarty M. F. Metformin may antagonize Lin28 and/or Lin28B activity, thereby boosting let 7 levels and antagonizing cancer progression. Med. Hypotheses 78, 262-269 (2012
91. Leone A., Di G. E., Bruzzese F., Avallone A. & Budillon A. New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat. Res. 159, 355-376 (2014
92. [No authors listed] Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854-865 (1998
93. Boussageon R., et al. Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes?. a systematic review. BMC Med. Res. Methodol. 13, 107 (2013
94. Hemmingsen B., et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ 344, e1771 (2012
95. Kurian B., Joshi R. & Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr. Pract. 14, 979-984 (2008
96. Hecking M., et al. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol. Dial. Transplant. 28, 550-566 (2013
97. Sharif A. Should metformin be our antiglycemic agent of choice post-transplantation?. Am. J. Transplant. 11, 1376-1381 (2011
98. Bajaj M., et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52, 1364-1370 (2003
99. Watkins P. B. Idiosyncratic liver injury: challenges and approaches. Toxicol. Pathol. 33, 1-5 (2005
100. Nissen S. E. & Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007
101. Luther P. & Baldwin D., Jr Pioglitazone in the management of diabetes mellitus after transplantation. Am. J. Transplant. 4, 2135-2138 (2004
102. Dormandy J. A., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279-1289 (2005
103. Tan M. H., et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 28, 544-550 (2005
104. Howard R. J., et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 73, 1923-1928 (2002
105. Ojo A. O., et al. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med. 349, 931-940 (2003
106. Holst J. J., Orskov C., Nielsen O. V. & Schwartz T. W. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 211, 169-174 (1987
107. Pederson R. A., Schubert H. E. & Brown J. C. The insulinotropic action of gastric inhibitory polypeptide. Can. J. Physiol. Pharmacol. 53, 217-223 (1975
108. Plamboeck A., et al. The effect of exogenous GLP 1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am. J. Physiol. Gastrointest. Liver Physiol. 304, G1117-G1127 (2013
109. Toft-Nielsen M. B., et al. Determinants of the impaired secretion of glucagon-like peptide 1 in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 86, 3717-3723 (2001
110. Nauck M. A., et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J. Clin. Invest. 91, 301-307 (1993
111. Idorn T., et al. Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease. Nephrol. Dial. Transplant. 29, 119-127 (2014
112. Orskov C., Wettergren A. & Holst J. J. Biological effects and metabolic rates of glucagonlike peptide 1 7-36 amide and glucagonlike peptide 1 7-37 in healthy subjects are indistinguishable. Diabetes 42, 658-661 (1993
113. Haidinger M., et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation- a randomized, double-blind, placebo-controlled trial. Am. J. Transplant. 14, 115-123 (2014
114. Lane J. T., et al. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation 92, e56-e57 (2011
115. Gueler I., et al. Effects of vildagliptin (Galvus(R)) therapy in patients with type 2 diabetes mellitus after heart transplantation. Drug Des. Devel. Ther. 7, 297-303 (2013
116. Sanyal D., Gupta S. & Das P. A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting. Indian J. Endocrinol. Metab. 17 (Suppl. 1), S203-S205 (2013
117. Wang X. M., Yang Y. J. & Wu Y. J. The emerging role of dipeptidyl peptidase 4 inhibitors in cardiovascular protection: current position and perspectives. Cardiovasc. Drugs Ther. 27, 297-307 (2013
118. Scirica B. M., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317-1326 (2013
119. White W. B., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369, 1327-1335 (2013
120. Nielsen L. L., Young A. A. & Parkes D. G. Pharmacology of exenatide (synthetic exendin 4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul. Pept. 117, 77-88 (2004
121. Kim D., et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30, 1487-1493 (2007
122. Kaakeh Y., Kanjee S., Boone K. & Sutton J. Liraglutide-induced acute kidney injury. Pharmacotherapy 32, e7-e11 (2012
123. Weise W. J., Sivanandy M. S., Block C. A. & Comi R. J. Exenatide-associated ischemic renal failure. Diabetes Care 32, e22-e23 (2009
124. Rahmoune H., et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non insulin dependent diabetes. Diabetes 54, 3427-3434 (2005
125. Mogensen C. E. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand. J. Clin. Lab. Invest. 28, 101-109 (1971
126. Nauck M. A., et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes. Metab. 16, 1111-1120 (2014
127. Yale J. F., et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes. Metab. 16, 1016-1027 (2014
128. Gilbert R. E. Sodium-glucose linked transporter 2 inhibitors: potential for renoprotection beyond blood glucose lowering?. Kidney Int. 86, 693-700 (2013
129. Kohan D. E., Fioretto P., Tang W. & List J. F. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 85, 962-971 (2014
130. Hornum M., Lindahl J. P., von Zur-Muhlen B., Jenssen T. & Feldt-Rasmussen B. Diagnosis, management and treatment of glucometabolic disorders emerging after kidney transplantation: a position statement from the Nordic Transplantation Societies. Transpl. Int. 26, 1049-1060 (2013
131. Hecking M., et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J. Am. Soc. Nephrol. 23, 739-749 (2012
132. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01683331?term=NCT01683331&rank=1 (2014
133. Weng J., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371, 1753-1760 (2008
134. Gerstein H. C., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 367, 319-328 (2012
135. Schmitz O., Brock B. & Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53 (Suppl. 3), S233-S238 (2004
136. Ryan G., Briscoe T. A. & Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des. Devel. Ther. 2, 203-214 (2009
137. Matschinsky F. M. Assessing the potential of glucokinase activators in diabetes therapy. Nat. Rev. Drug Discov. 8, 399-416 (2009
138. Bagger J. I., Knop F. K., Holst J. J. & Vilsboll T. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes. Metab. 13, 965-971 (2011
139. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02111096?term=NCT02111096&rank=1 (2015
140. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02119819?term=NCT02119819&rank=1 (2015
141. Hansen M., Sonne D. P. & Knop F. K. Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes. Curr. Diab. Rep. 14, 482 (2014
142. Bronden A., et al. Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential. Diabetes Obes. Metab. 17, 116-120 (2014
143. Yates C. J., Fourlanos S., Hjelmesaeth J., Colman P. G. & Cohney S. J. New-onset diabetes after kidney transplantation-changes and challenges. Am. J. Transplant. 12, 820-828 (2012